Our mission
Provide pioneering tools to guide physicians in the treatment of patients with immune-mediated disease, through prediction of long-term clinical prognosis.
Why prediction matters
Millions of people worldwide suffer from chronic and incurable immune-mediated inflammatory diseases such as inflammatory bowel disease, vasculitis and Lupus/SLE.
At diagnosis there is no way of knowing whether a patient is likely to experience a severe, relapsing form of the disease or a more quiescent and easier to manage pathway. The ability to stratify patients at the point of diagnosis will identify patients who may benefit from first line treatment with state-of-the-art anti-inflammatory drugs (biologics).
%
of specialist physicians see a need for a prognostic test.
%
of specialist physicians would use a test to predict outcomes
%
Reduction of associated treatment costs (based on UK data).
The PredictImmune solution
PredictImmune develops pioneering tools for guiding treatment options in immune-mediated inflammatory diseases with the first product addressing inflammatory bowel disease (both Crohn’s disease and ulcerative colitis).
Based on over 10 years of world-leading research at Cambridge University, UK, we have developed a simple lab test for Crohn’s and ulcerative colitis, using a small blood sample. The test accurately identifies patients who are at risk of experiencing severe, relapsing disease. These patients are likely to benefit from early biologics therapy. Physicians, patients and payors all recognise the value of such an approach to the management of inflammatory bowel disease.
